Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study

Critical Care

Volumn 18, Issue 3, 2014, Pages

  Blot, Stijn ^a   Koulenti, Despoina ^b,c,d   Akova, Murat ^e   Bassetti, Matteo ^f   De Waele, Jan J ^g   Dimopoulos, George ^d   Kaukonen, Kirsi Maija ^h,i   Martin, Claude ^j,k   Montravers, Philippe ^l   Rello, Jordi ^m   Rhodes, Andrew ⁿ   Starr, Therese ^b,c   Wallis, Steven C ^b   Lipman, Jeffrey ^b,c   Roberts, Jason A ^b,c  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e HACETTEPE UNIVERSITY   (Turkey)

^f SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ MONASH UNIVERSITY   (Australia)

^j HÔPITAL NORD   (France)

^k AzuRea Group   (France)

^l BICHAT HOSPITAL   (France)

^m UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

ⁿ ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; INTENSIVE CARE UNIT; INTERMITTENT DOSING; INTERMITTENT INFUSION; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; CRITICAL ILLNESS; DOSE RESPONSE; INTERNATIONAL COOPERATION; MIDDLE AGED;

ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84902544373     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13874     Document Type: Article

References (31)

1. Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010, 51:S183-S197. 10.1086/653519, 20731576.
2. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52:285-292. 10.1093/cid/cir034, 21217178.
3. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327. 10.1086/600877, 19569969.
4. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942. 10.2165/00003088-200443130-00005, 15509186.
5. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, Howden BP, Johnson PD. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2013, 57:1654-1663. 10.1128/AAC.01485-12, 3623342, 23335735.
6. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011, 52:975-981. 10.1093/cid/cir124, 21460309.
7. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851. 10.1097/CCM.0b013e3181961bff, 19237886.
8. Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011, 7:539-543. 10.1038/nrneurol.2011.141, 21769107.
9. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen K-M, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, . DALI Study Authors DALI: Defining Antibiotic Levels in Intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis 2014, 58:1072-1833. 10.1093/cid/ciu027, 24429437, DALI Study Authors.
10. Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012, 40:1523-1528. 10.1097/CCM.0b013e318241e553, 22511133.
11. Jamal JA, Economou CJ, Lipman J, Roberts JA. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012, 18:460-471. 10.1097/MCC.0b013e32835685ad, 22820155.
12. Li J, Udy AA, Kirkpatrick CM, Lipman J, Roberts JA. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. Int J Antimicrob Agents 2012, 39:69-72. 10.1016/j.ijantimicag.2011.08.017, 22024354.
13. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011, 55:2704-2709. 10.1128/AAC.01708-10, 3101407, 21402850.
14. Udy AA, Covajes C, Taccone FS, Jacobs F, Vincent JL, Lipman J, Roberts JA. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?. Int J Antimicrob Agents 2013, 41:564-568. 10.1016/j.ijantimicag.2013.01.018, 23473944.
15. Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents 2013, 41:255-260. 10.1016/j.ijantimicag.2012.10.015, 23312606.
16. Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother 2012, 56:634-638. 10.1128/AAC.05609-11, 3264249, 22123681.
17. Roberts JA, De Waele JJ, Dimopoulos G, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis 2012, 12:152. 10.1186/1471-2334-12-152, 3506523, 22768873.
18. Food and Drink Administration Guidance for industry: bioanalytical method validation. US Department of Health and Human Services, Center for Drug Evaluation and Research, Available at: [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformat ion/Guidances/UCM070107.pdf], Food and Drink Administration.
19. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984, 25:433-437. 10.1128/AAC.25.4.433, 185546, 6732213.
20. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010, 14:R53. 10.1186/cc8945, 2887170, 20370907.
21. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008, 23:422-430. 10.1016/j.jcrc.2007.11.011, 18725050.
22. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126. 10.1186/cc9091, 2945087, 20594297.
23. Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. Curr Opin Crit Care 2008, 14:390-396. 10.1097/MCC.0b013e3283021b3a, 18614901.
24. Blot S. MRSA pneumonia: better outcome through continuous infusion of vancomycin?. Crit Care Med 2005, 33:2127-2128. 10.1097/01.CCM.0000178288.70057.47, 16148496.
25. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45:2460-2467. 10.1128/AAC.45.9.2460-2467.2001, 90678, 11502515.
26. Akers KS, Cota JM, Chung KK, Renz EM, Mende K, Murray CK. Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy. J Burn Care Res 2012, 33:e254-e262. 10.1097/BCR.0b013e31825042fa, 22878490.
27. Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, Bernard L. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004, 29:351-357. 10.1111/j.1365-2710.2004.00572.x, 15271102.
28. Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Munoz E, Sirgo G, Olona M, Diaz E. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005, 33:1983-1987. 10.1097/01.CCM.0000178180.61305.1D, 16148469.
29. De Waele JJ, Danneels I, Depuydt P, Decruyenaere J, Bourgeois M, Hoste E. Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion. Int J Antimicrob Agents 2013, 41:434-438. 10.1016/j.ijantimicag.2012.12.015, 23410793.
30. Golenia BS, Levine AR, Moawad IM, Yeh DD, Arpino PA. Evaluation of a vancomycin dosing nomogram based on the modification of diet in renal disease equation in intensive care unit patients. J Crit Care 2013, 28:710-716. 10.1016/j.jcrc.2013.01.004, 23499418.
31. European Committee on Antimicrobial Susceptibility Testing Data from the EUCAST MIC distribution website. European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website, last accessed 09 May 2013 European Committee on Antimicrobial Susceptibility Testing.